Report cover image

Global Humanized Monoclonal Antibody Drugs Market Growth (Status and Outlook) 2025-2031

Publisher LP Information, Inc.
Published Aug 06, 2025
Length 130 Pages
SKU # LPI20281037

Description

According to this study, the global Humanized Monoclonal Antibody Drugs market size will reach US$ 259278 million by 2031.

Humanized monoclonal antibody drugs are therapeutic antibodies that are predominantly derived from human antibody structures, but with small portions—typically the complementarity-determining regions (CDRs)—originating from non-human species, such as mice. These drugs are engineered through recombinant DNA technology to reduce immunogenicity while maintaining high specificity and binding affinity to the target antigen. Humanized antibodies are widely used to treat cancers, autoimmune diseases, and inflammatory conditions.

United States market for Humanized Monoclonal Antibody Drugs is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Humanized Monoclonal Antibody Drugs is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Humanized Monoclonal Antibody Drugs is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Humanized Monoclonal Antibody Drugs players cover Merck & Co, AbbVie, Eli Lilly & Co, Roche, Takeda, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Humanized Monoclonal Antibody Drugs Industry Forecast” looks at past sales and reviews total world Humanized Monoclonal Antibody Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Humanized Monoclonal Antibody Drugs sales for 2025 through 2031. With Humanized Monoclonal Antibody Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Humanized Monoclonal Antibody Drugs industry.

This Insight Report provides a comprehensive analysis of the global Humanized Monoclonal Antibody Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Humanized Monoclonal Antibody Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Humanized Monoclonal Antibody Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Humanized Monoclonal Antibody Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Humanized Monoclonal Antibody Drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of Humanized Monoclonal Antibody Drugs market by product type, application, key players and key regions and countries.

Segmentation by Type:
Pembrolizumab
Risenqizumab
Orelizumab
Ixekizumab
Vedolizumab
Bevacizumab
Omalizumab
Farisimab
Trastuzumab
Other

Segmentation by Application:
Cancers
Autoimmune Diseases
Inflammatory Condition

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Merck & Co
AbbVie
Eli Lilly & Co
Roche
Takeda
GlaxoSmithKline
UCB
AstraZeneca
Biogen
Gilead Sciences
Novartis
Teva
Qilu Pharma
Sun Pharmaceutical
Johnson & Johnson
Beigene
Pfizer
Innovent Bio

Please note: The report will take approximately 2 business days to prepare and deliver.

Table of Contents

130 Pages
*This is a tentative TOC and the final deliverable is subject to change.*
1 Scope of the Report
2 Executive Summary
3 Humanized Monoclonal Antibody Drugs Market Size by Player
4 Humanized Monoclonal Antibody Drugs by Region
5 Americas
6 APAC
7 Europe
8 Middle East & Africa
9 Market Drivers, Challenges and Trends
10 Global Humanized Monoclonal Antibody Drugs Market Forecast
11 Key Players Analysis
12 Research Findings and Conclusion

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us